Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company's new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.

The new laboratory is part of Kamada's Quality Control laboratory network and represents a significant expansion of the Company's advanced testing capabilities for Anti-Rabies potency testing involved in the manufacture of KEDRAB® and KAMRAB®. The new laboratory is located in Kamada's plant in Beit Kama, Israel, and is one of a limited number of laboratories worldwide which can perform such tests. The new RFFIT laboratory was designed to meet stringent safety, quality and GMP standards. Prior to receiving the FDA approval, the laboratory was also approved by Health Canada and the Israeli Ministry of Health.

The RFFIT test is used by Kamada to quantify the Anti-Rabies potency throughout all key steps of KEDRAB and KAMRAB manufacturing from plasma collection and sourcing to final product release.

In 2025, Kamada's sales of KEDRAB and KAMRAB totaled over $70 million, representing the leading franchise in the company's portfolio of specialty plasma-derived products.